Organoids are advanced 3D culture systems that closely replicate human tissue architecture and function, offering physiologically relevant models for studying development, disease, and drug response. STEMCELL Technologies supports this research by providing high-quality reagents and defined media systems for the reliable establishment, expansion, and differentiation of organoid cultures.
High attrition in drug development, where fewer than 10% of candidates reach the market, is largely driven by poor translatability of animal models to human biology. To address this, we present human intestinal and hepatic organoid systems, both hPSC- and tissue-derived, as high-fidelity preclinical platforms for predicting toxicity and efficacy. Utilizing standardized culture media like HepatiCult™ and IntestiCult™, these models maintain donor-specific drug sensitivities and species-specific responses. Hepatic organoids demonstrated high sensitivity to drug-induced liver injury, effectively distinguishing between related compounds with different clinical severities and modeling cholestasis via CMFDA-based assays. Intestinal models across the duodenum, ileum, and colon reproduced region-specific barrier disruption, quantified through transepithelial electrical resistance and FITC-Dextran permeability. Furthermore, specialized organoid culture plates reduced experimental variability by 30% to 50% compared to traditional dome cultures. These scalable platforms provide a robust, predictive solution to de-risk therapeutic programs prior to clinical entry.
Speaker | Ayse Güven
